India is urged to make stents essential medicines to help control priceBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h3015 (Published 03 June 2015) Cite this as: BMJ 2015;350:h3015
- Sanjeet Bagcchi
The Maharashtra Food and Drug Administration (FDA) has urged the National Pharmaceutical Pricing Authority to make cardiac stents essential medicines to help control the price patients have to pay for them.
A recent survey by the Maharashtra FDA found that the maximum retail price of cardiac stents across India was 300-700% of their actual import cost. And the Economic Times newspaper reported that importers inflate the maximum retail price, domestic distributors sell the stents to hospitals at a profit margin of 125%, and then hospitals charge patients …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial